Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...
Read Full NewsThree medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be deterring patients. Not everyone agrees.
Despite FDA package insert recommendations, most patients with breast cancer who are prescribed CDK4/6 inhibitors do not receive liver function tests before starting treatment.
Patients who receive both standard medical treatment and complementary and alternative therapies have higher mortality — possibly due to reduced use of endocrine therapy and radiation.
1.
Sustained reduction found in prostate cancer mortality with prostate-specific antigen screening
2.
No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer
3.
A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma
4.
For elderly, unfit patients, the all-oral AML regimen shows promise.
5.
Physician Fights Insurer to Cover Her Baby's Brain Cancer Treatment
1.
Exploring the Benefits of Endari: How This Natural Remedy Can Help You Live a Healthier Life
2.
Understanding Mean Corpuscular Volume: A Comprehensive Guide
3.
Deep Learning Fluorescence Imaging for Oral Cancer Surgery: In Silico Depth Quantification
4.
Demystifying the Mentzer Index: Understanding Its Importance in Inventory Management
5.
Multiple Myeloma: Understanding the Basics
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
2.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
5.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge